OSE Immunotherapeutics SA (OSE.PA)
EUR 5.6
(0.63%)
EUR 5.6
(0.63%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 81.9 Million EUR | -10.66% |
| 2022 | 91.67 Million EUR | -9.7% |
| 2021 | 101.52 Million EUR | 4.83% |
| 2020 | 96.84 Million EUR | 8.95% |
| 2019 | 88.89 Million EUR | 15.59% |
| 2018 | 76.9 Million EUR | -0.58% |
| 2017 | 77.35 Million EUR | -13.62% |
| 2016 | 89.54 Million EUR | 426.9% |
| 2015 | 16.99 Million EUR | 758.33% |
| 2014 | 1.98 Million EUR | 489.29% |
| 2013 | 336 Thousand EUR | 19.15% |
| 2012 | 282 Thousand EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 140.92 Million EUR | 0.0% |
| 2023 FY | 81.9 Million EUR | -10.66% |
| 2023 Q2 | 80.39 Million EUR | 0.0% |
| 2023 Q4 | 81.9 Million EUR | 0.0% |
| 2022 FY | 91.67 Million EUR | -9.7% |
| 2022 Q4 | 91.67 Million EUR | 0.0% |
| 2022 Q2 | 102.26 Million EUR | 0.0% |
| 2021 FY | 101.52 Million EUR | 4.83% |
| 2021 Q4 | 101.52 Million EUR | 0.0% |
| 2021 Q2 | 98.21 Million EUR | 0.0% |
| 2020 Q4 | 96.97 Million EUR | 0.0% |
| 2020 FY | 96.84 Million EUR | 8.95% |
| 2020 Q2 | 90.74 Million EUR | 0.0% |
| 2019 FY | 88.89 Million EUR | 15.59% |
| 2019 Q4 | 88.89 Million EUR | 0.0% |
| 2019 Q2 | 94.91 Million EUR | 0.0% |
| 2018 FY | 76.9 Million EUR | -0.58% |
| 2018 Q4 | 76.9 Million EUR | 0.0% |
| 2018 Q2 | 84.62 Million EUR | 0.0% |
| 2017 FY | 77.35 Million EUR | -13.62% |
| 2017 Q2 | 79.44 Million EUR | 0.0% |
| 2017 Q4 | 77.35 Million EUR | 0.0% |
| 2016 Q2 | 82.65 Million EUR | 0.0% |
| 2016 FY | 89.54 Million EUR | 426.9% |
| 2016 Q4 | 89.54 Million EUR | 0.0% |
| 2015 FY | 16.99 Million EUR | 758.33% |
| 2015 Q2 | 19.27 Million EUR | 0.0% |
| 2015 Q4 | 16.99 Million EUR | 0.0% |
| 2014 FY | 1.98 Million EUR | 489.29% |
| 2014 Q4 | 1.98 Million EUR | 0.0% |
| 2014 Q2 | 2.85 Million EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2013 Q3 | 336 Thousand EUR | 0.0% |
| 2013 Q4 | 336 Thousand EUR | 0.0% |
| 2013 FY | 336 Thousand EUR | 19.15% |
| 2012 FY | 282 Thousand EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -456.764% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 74.959% |
| Adocia SA | 24.95 Million EUR | -228.178% |
| Aelis Farma SA | 26.28 Million EUR | -211.632% |
| Biophytis S.A. | 11.93 Million EUR | -586.16% |
| Advicenne S.A. | 12.4 Million EUR | -560.111% |
| genOway Société anonyme | 31.84 Million EUR | -157.204% |
| IntegraGen SA | 8 Million EUR | -923.705% |
| Medesis Pharma S.A. | 1.92 Million EUR | -4151.597% |
| Neovacs S.A. | 47.53 Million EUR | -72.299% |
| NFL Biosciences SA | 3.97 Million EUR | -1962.646% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -449.188% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -2085.882% |
| Sensorion SA | 46.49 Million EUR | -76.151% |
| Theranexus Société Anonyme | 7.23 Million EUR | -1031.569% |
| TME Pharma N.V. | 2.49 Million EUR | -3187.836% |
| Valbiotis SA | 33.24 Million EUR | -146.331% |
| TheraVet SA | 7.53 Million EUR | -987.045% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -132.182% |
| DBV Technologies S.A. | 165.65 Million USD | 50.559% |
| Genfit S.A. | 173.87 Million EUR | 52.896% |
| GeNeuro SA | 6.31 Million EUR | -1197.344% |
| Innate Pharma S.A. | 184.19 Million EUR | 55.536% |
| Inventiva S.A. | 69.13 Million EUR | -18.457% |
| MaaT Pharma SA | 42.93 Million EUR | -90.771% |
| MedinCell S.A. | 36.94 Million EUR | -121.663% |
| Nanobiotix S.A. | 93.89 Million EUR | 12.777% |
| Poxel S.A. | 4.82 Million EUR | -1598.113% |
| GenSight Biologics S.A. | 9.08 Million EUR | -801.288% |
| Transgene SA | 45.21 Million EUR | -81.127% |
| Valneva SE | 469.39 Million EUR | 82.552% |